OTCMKTS:LYRA Lyra Therapeutics Q4 2024 Earnings Report $0.20 0.00 (0.00%) As of 11:09 AM Eastern ProfileEarnings HistoryForecast Lyra Therapeutics EPS ResultsActual EPS-$8.00Consensus EPS -$6.00Beat/MissMissed by -$2.00One Year Ago EPS-$63.00Lyra Therapeutics Revenue ResultsActual Revenue$0.21 millionExpected Revenue$0.21 millionBeat/MissBeat by +$3.00 thousandYoY Revenue GrowthN/ALyra Therapeutics Announcement DetailsQuarterQ4 2024Date3/13/2025TimeBefore Market OpensConference Call DateThursday, March 13, 2025Conference Call Time4:00PM ETUpcoming EarningsLyra Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Lyra Therapeutics Earnings HeadlinesLyra Therapeutics Inc.August 29, 2026 | marketwatch.comLyra Therapeutics Ends Major Office Sublease AgreementApril 17, 2026 | tipranks.comThese 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAIElon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture after OpenAI, one some say could be 500 times bigger than ChatGPT. Test staff are said to be bound by law to keep details secret, and three lesser-known stocks may be tied to this next chapter in AI.September 2 at 1:00 AM | Stansberry Research (Ad)Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECApril 17, 2026 | globenewswire.comAfter layoffs, Lyra Therapeutics exits Watertown and Waltham leasesApril 14, 2026 | bizjournals.comTreating allergic fungal rhinosinusitis in childrenApril 8, 2026 | msn.comSee More Lyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email. Email Address About Lyra TherapeuticsLyra Therapeutics (OTCMKTS:LYRA) is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects. The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology. Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas. View Lyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond ObesityFrom High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend PayoutsUlta Beauty’s Earnings Beat Was Stronger Than the Stock’s ReactionNVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI MoatMedtronic’s Stars Are Aligning for a Price RecoverySalesforce Looks Overbought, But the Rally May Be Far From OverIs Abercrombie & Fitch's Hot Streak Just Getting Started? Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
